A real-world study to determine incidence and risk factors of SARS-CoV-2 breakthrough infections in North Carolina COVID-19 community research partnership (NC-CCRP)
Latest Information Update: 02 Feb 2023
At a glance
- Drugs Ad26.COV2 S (Primary) ; Tozinameran (Primary) ; Elasomeran
- Indications COVID 2019 infections
- Focus Adverse reactions
Most Recent Events
- 02 Feb 2023 New trial record